 |
|
|
| |
Discontinuation of Dolutegravir (DTG)-based Regimens in Clinical Practice
|
| |
| |
Reported by Jules Levin
HIV Glasgow 2016 Oct 23-26
Vivancos-Gallego, MJ1; Moreno, A1; Perez Elias, MJ1; Gomez Ayerbe, C1; Casado, JL1; Quereda, C1; Sanchez-Conde, M1; Serrano Villar, S1; Dronda, F1; Navas, E1; Rodriguez, MA2; Moreno, S1.
Hospital Ramón y Cajal, IRYCIS Infectious Diseases Madrid Spain1; Hospital Ramón y Cajal, IRYCIS Pharmacy Department Madrid Spain2
- In our real life cohort we did find a high proportion of DTG discontinuation that was attributable not only to toxicity.
- CNS adverse events are the most frequent cause of discontinuation.
- Ongoing pharmacovigilance is important to identify events that might be associated with the drug.
|
| |
|
|
|
|
|
